The book “STEM CELL THERAPY FOR ORGAN FAILURES” edited by Dr. S. Indumathi demonstrates the In Vitro and In vivo therapeutic strategies and applications of pre- and post-natal stem cells for treating the failures of various organ systems of our body in a wide perspective. It explores the past, present and the futuristic approach of the exciting field of stem cells and its intriguing properties involved in tissue repair and regeneration. The prime focus of this volume is to unravel the basic, advanced, therapeutic and translational approaches put-forth so far in the field of stem cells and regenerative medicine at research, pre-clinical and clinical levels. Stem cells has ushered in widespread interest and exciting possibilities for cell based therapies, albeit failures do prevail and small uncontrolled phase I/II studies are only signals generating, rather than definite proof of concept thereby limiting its applicability in curative therapeutics. Despite certain initiatives and meticulous untiring efforts, bringing this basic bench side research into advanced transitional bedside remained a challenge. Thus, this book embarked upon the expanding researches in these areas that seem decisive in improvising regenerative medical therapeutics, thereby leading to further path-breaking studies that cure all health challenges facing mankind. Overall, this book reveals the imperativeness of various stem cell sources and its utility in curative therapeutics.

This book examines the application of stem cell surgery for diabetes and heart failure. Organized into two sections, the first identifies and summarizes the current worldwide stem cell trials for heart failure. Subsequent chapters in part two analyze the current worldwide stem cell trials in patients with Diabetes Mellitus. Both sections utilize studies that include non-expanded stem cells; each study is grouped by stem cell type and geographic location. Stem Cell Surgery Trials in Diabetes and Heart Failure is a comprehensive, convenient reference for cardiologists, endocrinologists, internists, and family physicians.

Buku Basic Concepts in Stem Cell Therapy Stem Cell Therapy Strategy Development for Embryo ini disusun dengan tujuan sebagai referensi bahan ajar dan belajar para akademisi pendidikan dengan kelas bilingual yaitu berbahasa inggris. Berisikan 12 bab yang membahas tentang stem cell, mulai dari deffinisi, jenis biologis, terapi dan pedoman stem cell.

In multicellular organisms, communication between cells involves secretion of proteins that bind to receptors on neighboring cells. While this has been well documented, another mode of intercellular communication has recently become the subject of increasing interest: the release of exosomes. In cancer, tumor exosomes are involved in various aspects of pathogenesis, including proliferation, immunosuppression, and metastasis. Given the ability of exosomes to export unneeded endogenous molecules from cells, these structures hold great potential as anticancer therapeutic agents. They are also being studied as prognostic markers for cancer.

The major advances in the field of biotechnology and molecular biology in the twenty-first century have led to a better understanding of the pathophysiology of diseases. A new generation of biopharmaceuticals has emerged, including a wide and heterogeneous range of innovative cell and gene therapies. These therapies aim to prevent or treat chronic and serious life-threatening diseases, previously considered incurable. This book describes the evolution and adaptation of the regulatory environment to assess these therapies in contrast with the resistance of health technology assessment (HTA) agencies and payers to acknowledge the specificity of cell and gene therapies and the need to adapt existing decision-making frameworks. This book provides insights on the learnings from the experience of current cell and gene therapies (regulatory approval, HTA, and market access), in addition to future trends to enhance patient access to these therapies. Key Features: Describes the potential change of treatment paradigm and the specificity of cell and gene therapies, including the gradual move from repeated treatment administration to one-time single administration with the potential to be definite cure Highlights the challenges at the HTA level Discusses the affordability of future cell and gene therapies and the possible challenges for health insurance systems Provides potential solutions to address these challenges and ensure patient access to innovation while maintaining the sustainability of healthcare systems

Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohn’s disease, diabetes, multiple sclerosis, critical limb ischemia and many others. MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within the bone marrow with the ability to form clonogenic colonies in vitro. In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell population’s phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing steps needed for the clinical application of MSCs, including isolation from various tissues, scalable in vitro expansion, cell banking, dose preparation, quality control parameters, delivery methods and numerous others are being extensively studied. Despite a significant number of ongoing clinical trials, none of the current therapeutic approaches have, at this point, become a standard of care treatment. Although exceptionally promising, the clinical translation of MSC-based therapies is still a work in progress. The extensive number of ongoing clinical trials is expected to provide a clearer path forward for the realization and implementation of MSCs in regenerative medicine. Towards this end, reviews of current clinical trial results and discussions of relevant topics association with the clinical application of MSCs are compiled in this book from some of the leading researchers in this exciting and rapidly advancing field. Although not absolutely all-inclusive, we hope the chapters within this book can promote and enable a better understanding of the translation of MSCs from bench-to-bedside and inspire researchers to further explore this promising and quickly evolving field.

Vols. for 1963- include as pt. 2 of the Jan. issue: Medical subject headings.

Stem Cells and Biomaterials for Regenerative Medicine addresses the urgent need for a compact source of information on both the cellular and biomaterial aspects of regenerative medicine. By developing a mutual understanding between three separately functioning areas of science—medicine, the latest technology, and clinical economics—the volume encourages interdisciplinary relationships that will lead to solutions for the significant challenges faced by today's regenerative medicine. Users will find sections on the homeostatic balance created by apoptosis and proliferating tissue stem cells, the naturally regenerative capacities of various tissue types, the potential regenerative benefits of iPS-generation, various differentiation protocols, and more. Written in easily accessbile language, this volume is appropriate for any professional or medical staff looking to expand their knowledge with regard to stem cells and regenerative medicine. - Arms readers with key information on tissue engineering, artificial organs and biomaterials, while using broadly accessible language - Provides broad introduction to, and examples of, various types of stem cells, core concepts of regenerative medicine, biomaterials, nanotechnology and nanomaterials, somatic cell transdyferentiation, and more - Edited and authored by researchers with expertise in regenerative medicine, (cancer) stem cells, biomaterials, genetics and nanomaterials